These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38835773)

  • 1. Immunotherapy in the context of sepsis-induced immunological dysregulation.
    Wu Y; Wang L; Li Y; Cao Y; Wang M; Deng Z; Kang H
    Front Immunol; 2024; 15():1391395. PubMed ID: 38835773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?
    Boomer JS; Green JM; Hotchkiss RS
    Virulence; 2014 Jan; 5(1):45-56. PubMed ID: 24067565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation and Cell Death of the Innate and Adaptive Immune System during Sepsis.
    Nedeva C
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immune System Regulation in Sepsis: From Innate to Adaptive.
    Qiu Y; Tu GW; Ju MJ; Yang C; Luo Z
    Curr Protein Pept Sci; 2019; 20(8):799-816. PubMed ID: 30843486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in sepsis - brake or accelerate?
    Steinhagen F; Schmidt SV; Schewe JC; Peukert K; Klinman DM; Bode C
    Pharmacol Ther; 2020 Apr; 208():107476. PubMed ID: 31931100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 signaling pathway in sepsis: Does it have a future?
    Chen R; Zhou L
    Clin Immunol; 2021 Aug; 229():108742. PubMed ID: 33905818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic Cells in Sepsis: Pathological Alterations and Therapeutic Implications.
    Wu DD; Li T; Ji XY
    J Immunol Res; 2017; 2017():3591248. PubMed ID: 29075648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral Delivery of IL-7 Is a Potent Immunotherapy Stimulating Innate and Adaptive Immunity and Confers Survival in Sepsis Models.
    Lélu K; Dubois C; Evlachev A; Crausaz M; Baldazza M; Kehrer N; Brandely R; Schlesinger Y; Silvestre N; Marchand JB; Bastien B; Leung-Theung-Long S; Unsinger J; Martin P; Inchauspé G
    J Immunol; 2022 Jul; 209(1):99-117. PubMed ID: 35667841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy.
    Hotchkiss RS; Monneret G; Payen D
    Nat Rev Immunol; 2013 Dec; 13(12):862-74. PubMed ID: 24232462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision Immunotherapy for Sepsis.
    Peters van Ton AM; Kox M; Abdo WF; Pickkers P
    Front Immunol; 2018; 9():1926. PubMed ID: 30233566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.
    Meng Z; Chen Y; Lu M
    Front Immunol; 2019; 10():3127. PubMed ID: 32117201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
    Patil NK; Bohannon JK; Sherwood ER
    Pharmacol Res; 2016 Sep; 111():688-702. PubMed ID: 27468649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus: from immunobiology to immunotherapy.
    Grimm D; Heeg M; Thimme R
    Clin Sci (Lond); 2013 Jan; 124(2):77-85. PubMed ID: 23013042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards personalized medicine: a scoping review of immunotherapy in sepsis.
    Slim MA; van Mourik N; Bakkerus L; Fuller K; Acharya L; Giannidis T; Dionne JC; Oczkowski SJW; Netea MG; Pickkers P; Giamarellos-Bourboulis EJ; Müller MCA; van der Poll T; Wiersinga WJ; ; Vlaar APJ; van Vught LA
    Crit Care; 2024 May; 28(1):183. PubMed ID: 38807151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomaterial-Driven Immunomodulation: Cell Biology-Based Strategies to Mitigate Severe Inflammation and Sepsis.
    Lasola JJM; Kamdem H; McDaniel MW; Pearson RM
    Front Immunol; 2020; 11():1726. PubMed ID: 32849612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune dysregulation in sepsis: experiences, lessons and perspectives.
    Cao M; Wang G; Xie J
    Cell Death Discov; 2023 Dec; 9(1):465. PubMed ID: 38114466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of naïve dendritic cells in resolving post-sepsis long-term immunosuppression.
    Laudanski K
    Med Hypotheses; 2012 Oct; 79(4):478-80. PubMed ID: 22840328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis.
    Cao C; Yu M; Chai Y
    Cell Death Dis; 2019 Oct; 10(10):782. PubMed ID: 31611560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity.
    Uher O; Caisova V; Hansen P; Kopecky J; Chmelar J; Zhuang Z; Zenka J; Pacak K
    Semin Oncol; 2019; 46(4-5):385-392. PubMed ID: 31739997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staging and Personalized Intervention for Infection and Sepsis.
    Beckmann N; Salyer CE; Crisologo PA; Nomellini V; Caldwell CC
    Surg Infect (Larchmt); 2020 Nov; 21(9):732-744. PubMed ID: 32240042
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.